Clinical trials
Phase 3 Fallopian Tube Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
100 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 5 |
| 2003 | 2 |
| 2004 | 2 |
| 2005 | 5 |
| 2006 | 2 |
| 2007 | 4 |
| 2009 | 5 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 5 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 6 |
| 2019 | 4 |
| 2020 | 6 |
| 2021 | 4 |
| 2022 | 7 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 7 |
| 2026 | 9 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 43 |
| Recruiting | 15 |
| Unknown status | 15 |
| Active, not recruiting | 13 |
| Not yet recruiting | 6 |
| Terminated | 5 |
| Withdrawn | 3 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 6 |
| Merck Sharp & Dohme LLC | 5 |
| AGO Study Group | 4 |
| Medical Research Council | 4 |
| pharmaand GmbH | 4 |
| Alliance for Clinical Trials in Oncology | 3 |
| Amgen | 3 |
| Eli Lilly and Company | 3 |
| GOG Foundation | 3 |
| Genmab | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fallopian Tube Neoplasms | 100 |
| Ovarian Neoplasms | 78 |
| Carcinoma, Ovarian Epithelial | 43 |
| Peritoneal Neoplasms | 12 |
| Brenner Tumor | 7 |
| Endometrial Neoplasms | 6 |
| Neoplasms | 5 |
| Uterine Cervical Neoplasms | 5 |
| Recurrence | 4 |
| Breast Neoplasms | 3 |
Trials
Showing 51 to 75 of 100. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.